1. Home page
  2. Search

Chemoradiotherapy combined with intracavitary hyperthermia for anal cancer: Feasibility and long-term results from a phase II randomized trial

This item is provided by the institution :
National Technical University of Athens   

Repository :
Digital Library of National Technical University of Athens | Dspace@NTUA   

see the original item page
in the repository's web site and access all digital files if the item*



Chemoradiotherapy combined with intracavitary hyperthermia for anal cancer: Feasibility and long-term results from a phase II randomized trial (EN)
Dardoufas, C (EN)
Gennatas, C (EN)
Vlahos, L (EN)
Kouloulias, V (EN)
Plataniotis, G (EN)
Kouvaris, J (EN)
Papavasiliou, C (EN)
Uzunoglu, N (EN)
journalArticle (EN)
2014-03-01T01:21:59Z
2005 (EN)
Purpose: The purpose of this study was to investigate in a randomized way the clinical benefit of addition of intracavitary hyperthermia (ICHT) to a conventional chemoradiotherapy schedule in patients with T2-T3N0M0 anal cancer. Methods and Materials: Patients were randomly assigned to undergo chemotherapy with 5-fluorouracil (5-FU) and mitomycin-C combined with radiotherapy with (arm A: 24 patients) or without ICHT (arm 13: 25 patients). A microwave applicator operating at 43 3 MHz inserted into the anal-rectal cavity was used for ICHT. Patients in both aims received 1000 mg/m(2) per day of 5-FU on days 1-4 and days 28-31 plus 15 mg/m(2) mitomycin-C on day 1. Radiotherapy was administered with a dose of 41.4 Gy (1.8 Gy per fraction) plus a booster dose of 14 Gy (2 Gy per fraction). Results: One patient from group A developed severe mucositis, whereas no severe morbidity was noted in the rest of the patients in both groups. The incidence of lower-intestine acute reactions was higher in the ICHT arm. After a 5-year follow up in the hyperthermia arm, 23 of 24 patients (95.8%) preserved their anorectal function and avoided permanent colostomy, whereas in the second arm, 17 of 25 (68.0%) had sphincter preservation. Local recurrence-free survival time was significantly higher in the ICHT arm (P = 0.0107, log rank test), whereas no significant difference in overall survival was note I. Conclusion: The addition of ICHT to the chemoradiotherapy schedule of anal cancer seems to offer a new effective and safe therapeutic modality. The preservation of anorectal function seems to be the significant clinical benefit of adjuvant ICHT. (EN)
Oncology (EN)
mitomycin C (EN)
Humans (EN)
Middle Aged (EN)
skin toxicity (EN)
bladder disease (EN)
blood toxicity (EN)
Diathermy (EN)
Male (EN)
fluorouracil (EN)
anus cancer (EN)
controlled clinical trial (EN)
enteropathy (EN)
microwave irradiation (EN)
Dose Fractionation (EN)
Female (EN)
radiation dose (EN)
female (EN)
morbidity (EN)
human (EN)
Fluorouracil (EN)
clinical trial (EN)
Mitomycin (EN)
colostomy (EN)
Anal cancer (EN)
anus (EN)
survival (EN)
aged (EN)
Antineoplastic Combined Chemotherapy Protocols (EN)
Combined Modality Therapy (EN)
Radiotherapy (EN)
recurrent disease (EN)
Anus Neoplasms (EN)
article (EN)
randomized controlled trial (EN)
hyperthermic therapy (EN)
controlled study (EN)
5-fluoroucil and mitomycin (EN)
Survival Analysis (EN)
Randomized study (EN)
rectum (EN)
Aged (EN)
adult (EN)
anus sphincter (EN)
Intracavitary hyperthermia (EN)
male (EN)
American Journal of Clinical Oncology: Cancer Clinical Trials (EN)
English
LIPPINCOTT WILLIAMS & WILKINS (EN)
National Technical University of Athens
Digital Library of National Technical University of Athens | Dspace@NTUA
Κεντρική Βιβλιοθήκη Ε.Μ.Π.
Ιδρυματικό Αποθετήριο
Δημοσιεύσεις μελών Δ.Ε.Π. σε περιοδικά



*Institutions are responsible for keeping their URLs functional (digital file, item page in repository site)